21 August 2025 in PLOS ONE
The complications and lingering effects of COVID-19 have caused a global health crisis, prompting intense investigations into the mechanism by which SARS-CoV-2 causes the disease. The majority of symptoms associated with this infectious disease are linked to mitochondrial dysfunction, and recent studies indicate that SARS-CoV-2 can impair host mitochondrial function. This study aims to investigate mutations in the MT-CYB and MT-ATP6 genes of mtDNA in COVID-19 patients and their association with disease outcomes. Out of 110 individuals enrolled, 30 were diagnosed with COVID-19, while the remaining 80 were healthy. Following DNA isolation from the blood samples, the MT-CYB and MT-ATP6 genes were amplified through PCR, purified, and sequenced using Sanger sequencing. In the MT-CYB gene, 9 distinct mutations were found. Among these, novel mutation m.14942A > C was more prevalent in COVID-19-positive individuals than COVID-19 negative controls (p = 0.012 < 0.05) and exhibited a significant correlation with the disease as OR (95% CI) = 19.75 (2.264–172.246). According to in-silico analyses, this mutation is deemed deleterious and decreases the stability of the CYB protein. In case of the MT-ATP6 gene, among the identified 8 mutations, the m.8744T > G mutation was higher in COVID-19-positive individuals than healthy controls (p = 0.009 < 0.05) and showed a significant correlation with the disease: OR (95% CI) = 24.04 (2.81–205.62). According to in-silico analyses, this mutation is found to be pathogenic and reduces the stability of the ATP6 protein. In conclusion, one novel mtDNA mutation was identified in this study, and some of the mutations identified in the MT-CYB as well as MT-ATP6 genes, including the novel mutation, are relatively common in the COVID-19 patient group. Moreover, the findings demonstrated that these mutations may contribute to the pathogenesis of COVID-19.
29 January 2025 in Advances in Pharmacological and Pharmaceutical Sciences
Metformin is the most widely prescribed drug for the treatment of Type 2 diabetes mellitus (T2DM), but its response varies from person to person. This study aims to analyze the complete mutation spectrum of the OCT1 gene in metformin poor responders and to explore the potential pathogenic effects of the identified mutations. Clinical features of 56 Bangladeshi T2DM patients (who showed altered response to metformin) were analyzed, and genomic DNA was extracted from their blood samples. Subsequently, the entire exons (1–11), along with flanking introns of the OCT1 gene were amplified and sequenced. Molecular consequences of the identified mutations on OCT1 protein activity were determined through in silico analyses. In this study, 29 mutations of the OCT1 gene were identified; among which 5 mutations (c.412‐86G>T, c.970G>C, c.1386‐3088_1386‐3083delGAATCA, c.1498+66G>T, and c.1653C>A) were novel. It was found that nsSNPs c.181C>T, c.1022C>T, c.493G>T, c.1207A>G, and c.970G>C (novel) as well as frameshift deletions have potential deleterious effects on OCT1 protein stability and function. Some of these mutations also cause alternative splicing, as per the HSF tool. In addition, alteration of interatomic bonding in the OCT1 protein due to two high‐risk mutations (c.181C>T and c.1022C>T) was found from web‐based analysis. The mutations, as mentioned earlier, are the most probable causative factor of decreased metformin effectiveness and adverse side effects in T2DM patients who are poor responders. Understanding the OCT1 gene variations of patients can help tailor treatment strategies for optimal metformin response or identify alternative medications.
18 September 2026 in Gene & Protein in Disease
Variability in COVID-19 disease severity suggests that host genetic factors influence immune responses and disease outcomes. Tyrosine kinase 2 (TYK2), encoded by the TYK2 gene, helps regulate immune responses and inflammation. However, the impacts of its variants on disease progression remain unclear. This study investigated the association between single-nucleotide polymorphisms (SNPs) in the TYK2 gene and COVID-19 severity. The study enrolled COVID-19 patients, with one group presenting severe symptoms and another group with mild symptoms. After DNA extraction, a specific region of the TYK2 gene was amplified and sequenced. Three SNPs were identified within the targeted region: rs2304255 (C>T), rs2304256 (C>A), and rs12720270 (G>A). Among these, rs2304256 (a missense variant) and rs12720270 (an intronic variant) showed significantly different allele frequencies between mild and severe COVID-19 groups. Computational predictions suggested that the identified missense mutations do not directly affect TYK2 protein function. However, expression quantitative trait locus analysis from the Genotype–Tissue Expression database indicated that rs2304256 and rs12720270 are associated with increased TYK2 expression. Furthermore, RNA sequencing data analysis suggested that these variants promote exon 8 inclusion in TYK2 mRNA. As higher levels of full-length TYK2 potentially cause cytokine over-signaling, SNPs rs2304256 and rs12720270 may contribute to exaggerated inflammatory responses during COVID-19, increasing disease severity.